Patients have a right to decline or withdraw LVADs. Informed consent and shared decision making is not easy, however, with treatments that are high risk, high reward.
AMA J Ethics. 2019; 21(5):E394-400. doi:
10.1001/amajethics.2019.394.
Despite challenges of decision making for unrepresented patients, few laws or policy statements offer solutions. This article offers 5 key things to do.
AMA J Ethics. 2019; 21(7):E582-586. doi:
10.1001/amajethics.2019.582.
A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs.
AMA J Ethics. 2019; 21(7):E611-616. doi:
10.1001/amajethics.2019.611.